Clinical assessment of prophylactic chemotherapy in treating with hydatidiform mole
A protocol for systematic review and meta-analysis

Feng Xu, MD, Yan-Li Zheng, MD, Xiao-Yan Lu, MD, Hai-Feng Qiao, MD, Ying Wang, MD*

Abstract

Background: Hydatidiform mole (HM) is more common as molar pregnancy. It is a disease classified under the category of gestational trophoblastic diseases, which could metastasize after originating in the placenta. A majority of females suffering from molar pregnancies are curable by evacuating retained products of conception and the patient’s fertility is preserved. In some cases, the growth perseveres and leads to gestational trophoblastic neoplasia, which is an extremely malignant condition that needs chemosensitization. Therefore, we will conduct this research to assess both the efficacy and as well as the safety of using prophylactic chemotherapy to treat HM.

Methods: In the preliminary review, the authors will search for randomized controlled trials involving prophylactic chemotherapy to treat HM. The literature search is carried out in the following electronic databases from their inception to May 2021: Chinese National Knowledge Infrastructure, Chinese BioMedical Literature, and WanFang database are the three Chinese language databases. Web of Science, PubMed, Cochrane Library, and EMBASE are the four English language databases. The authors will also perform a manual search through the bibliographies in related literature to find extra articles and ongoing studies. Two independent authors will assess the literature according to an inclusion criteria, use a specialized data collection table to extract data, and use the Cochrane ‘Risk of bias’ tool for evaluating any possible bias risk in the selected articles. Data synthesis and statistical operations are completed with the RevMan software (v. 5.3).

Results: The present systematic analysis provides a rationalized synthesis of existing evidence related to the use of prophylactic chemotherapy in the treatment of HM.

Conclusion: Our findings will summarize the current evidences for prophylactic chemotherapy in the treatment of HM.

Ethics and dissemination: An ethics approval is nonrequired because pre published results will be used.

Registration number: DOI 10.17605/OSF.IO/6QV52 (https://osf.io/6qv52/)

Abbreviations: GTN = gestational trophoblastic disease, HM = hydatidiform mole.

Keywords: efficacy, hydatidiform mole, meta, prophylactic chemotherapy, safety

1. Introduction

Gestational trophoblastic disease (GTN) refers to a condition characterized by a relentless autonomous excessive growth of embryonic chorionic tissue or trophoblast. [1,2] Hydatidiform mole (HM), commonly referred to as molar pregnancy is classified under the category of GTN, which has a metastasizing probability after originating in the placenta. HM is categorized as a whole and part mole according to the gross morphology, histopathology, and karyotype, and is generally regarded as a non-invasive type of GTN. [3-6] Even though HM is regarded as benign, they are pre-malignant and has the likelihood to turn invasive and malignant. Vaginal bleeding is the most common symptom of HM. Accompanying symptoms are more common in complete mole, including theca lutein ovarian cysts, hyperthyroidism, and excessive uterine enlargement. Still, such conditions are far less prevalent because frequent ultrasound scans lead to early diagnosis. [7] The conception’s retained products are evacuated in females who desire to preserve their fertility, preferably by suction curettage, to completely eradicate all
trophoblastic tissue.[7] A majority of the cases can be treated in such a manner. However, in some females, HM remains prevalent and advances to a malignant nature that requires chemo-based treatment.[8,9]

GTN is a condition that is extremely chemo-sensitive, and different chemotherapeutic agents have achieved decent rates of cure. According to the level of GTN, it is either classified as low- or high-risk GTN. Over the recent years, the therapeutic strategy used to treat low-risk GTN has remained largely unchanged. All females with “low-risk” GTN and nearly 85% of females with “high-risk” GTN are treated and healed using a single chemo agent or a combination of chemo-based treatments.[7,10,11] Dactinomycin and methotrexate are widely regarded to be fairly safe agents as the first-line of chemo for GTN, either singularly or combined with other chemotherapeutic agents.[12,13] The first usage of prophylactic chemo for females with HM took place in 1966.[14] Until now, no previous research has explored the effectiveness and safety of prophylactic chemotherapy in the treatment of HM. Therefore, in the present research, we will assess the efficacy and security of using prophylactic chemotherapy to treat HM.

2. Objective
The aim of this meta-analysis is to systematically investigate the effectiveness and safety associated with the use of prophylactic chemotherapy to treat HM.

3. Methods
3.1. Study registration
This study will be conducted according to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). This study is registered in the OSF (https://osf.io/) with DOI 10.17605/OSF.IO/6QV52.

3.2. Criteria for considering studies for this study
3.2.1. Types of studies. The authors will consider all randomized controlled trials as well previously published articles that have evaluated the use of prophylactic chemotherapy to treat HM.

3.2.2. Types of participants. All females diagnosed with HM are considered as participants. No restrictions will be applied in terms of age, country, and ethnicity.

3.2.3. Types of interventions/comparisons. All participants in the experimental group must have received prophylactic chemotherapy. Those in the control group must have been treated with placebo, analgesic drugs, or no treatment.

3.2.4. Types of outcomes. The primary outcomes are incidence of GTN, which includes invasive mole, choriocarcinoma, and both epitheloid trophoblastic and placental site tumors. The secondary outcomes include time to diagnose GTN, occurrence of successive pregnancies, overall survival, drug toxicity, and standard of life.

3.3. Search methods for identification of studies
In the preliminary review, the authors will search for randomized controlled trials involving prophylactic chemotherapy to treat HM. The literature search is carried out in the following electronic databases from their inception to May 2021: Chinese National Knowledge Infrastructure, Chinese BioMedical Literature, and WanFang database are the three Chinese language databases. Web of Science, PubMed, Cochrane Library, and EMBASE are the 4 English language databases. The authors will also perform a manual search through the bibliographies in related literature to find extra articles and ongoing research. The following search terms will be used individually or in combinations: “hydatidiform mole,” “prophylactic chemotherapy,” AND “randomized controlled trial.”

3.4. Data collection and analysis
3.4.1. Selection of studies. Two independent authors will review the retrieved studies. Briefly, they will exclude duplicate articles and studies that do not match the inclusion criteria by reading titles/abstracts. Afterwards, the full-texts are scrutinized, having met the above criteria, the studies are selected for further screening and will be included in the meta-analysis. A third author will evaluate any discrepancies if necessary. Figure 1 is a summary of the process that will be used for selecting studies.

3.4.2. Data extraction and management. A pair of autonomous authors will use a specially designed data collection table to extract data and summarize details from selected studies. All the data that are extracted shall be reviewed for accuracy and completeness. The extracted information will include study characteristics (study type, publication date, country, and ethnicity), design (method, intervention chemotherapy regimen, and dosage), and outcome measures. A third author will evaluate any discrepancies if necessary.

3.4.3. Assessment of risk of bias. The authors will employ the Cochrane Collaboration tool to assess the bias risk in the studies selected.[15] A third author will evaluate any discrepancies if necessary.

3.4.4. Measures of treatment effect. Dichotomous outcomes are presented as relative risk and 95% confidence intervals, whereas continuous outcomes are presented as mean differences or standardized mean differences and 95% confidence intervals.

3.4.5. Assessment of heterogeneity. The authors are planning to use the $\chi^2$ test and $I^2$ statistic to determine statistical heterogeneity. If the $P < .1$ or $I^2 > 50\%$, the random-effect model will be employed for analysis. Else, if the $P > .1$ or the $I^2 < 50\%$, then the fixed-effect model will be employed.

3.4.6. Assessment of reporting biases. If applicable, the potential bias in publication will be assessed using Funnel plots. Meanwhile, asymmetry on the funnel plot will also be checked using Egger test.

3.4.7. Sensitivity analysis. The authors are also planning to conduct a sensitivity analysis to assess the robustness of the results.

4. Discussion
Scholars predict that prophylactic chemotherapy has a significant role in the treatment of HM patients. Yet, up to date, published studies related to the use of prophylactic chemotherapy on HM have been mostly theoretical. Considering the growing body of
literature on prophylactic chemotherapy for HM, it is useful to conduct a systematic meta-analysis to determine the efficacy and safety of using prophylactic chemotherapy to treat HM patients. Therefore, this study will summarize the existing body of knowledge related to the efficacy and safeness of prophylactic chemotherapy for treating HM. Therefore, the outcomes of the study will provide dependable references for practitioners and patients when treating HM patients with prophylactic chemotherapy. Most importantly, the results could provide policymakers with fresh insights to an alternative form of prophylactic chemotherapy therapy.

**Author contributions**

Conceptualization: Feng Xu.  
Data curation: Yan-Li Zheng, Xiao-Yan Lu, Hai-Feng Qiao.  
Formal analysis: Feng Xu, Xiao-Yan Lu, Hai-Feng Qiao, Ying Wang.  
Funding acquisition: Yan-Li Zheng, Ying Wang.  
Investigation: Yan-Li Zheng.  
Methodology: Feng Xu, Xiao-Yan Lu, Hai-Feng Qiao.  
Project administration: Feng Xu, Xiao-Yan Lu.  
Resources: Hai-Feng Qiao, Ying Wang.
Software: Yan-Li Zheng.
 Supervision: Xiao-Yan Lu.
 Validation: Yan-Li Zheng, Hai-Feng Qiao.
 Visualization: Feng Xu.
 Writing – original draft: Feng Xu.
 Writing – review & editing: Ying Wang.

References

[1] Sharami SRY, Saffarich E. A review on management of gestational trophoblastic neoplasia. J Family Med Prim Care 2020;9:1287–95.
[2] Sebire NJ, Seckl MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ 2008;337:a1193.
[3] Mittal S, Menon S. Interstitial pregnancy mimicking an invasive hydatidiform mole. Am J Obstet Gynecol 2019;220:501.
[4] Sarmadi S, Izadi-Mood N, Sanii S, et al. Inter-observer variability in the histologic criteria of diagnosis of hydatidiform moles. Malays J Pathol 2019;41:15–24.
[5] Ning F, Hou H, Morse AN, et al. Understanding and management of gestational trophoblastic disease. F1000Res 2019;8.
[6] Sebire NJ. Histopathological diagnosis of hydatidiform mole: contemporary features and clinical implications. Fetal Pediatr Pathol 2010;29:1–16.
[7] Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376:717–29.
[8] Sato S, Yamamoto E, Niimi K, et al. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia. Int J Clin Oncol 2020;25:203–9.
[9] Goto S, Ito K, Mitsui T, et al. Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol 2004;93:529–35.
[10] Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am 2012;26:111–31.
[11] Niemann I, Vejerslev LO, Froding L, et al. Gestational trophoblastic diseases—clinical guidelines for diagnosis, treatment, follow-up, and counselling. Dan Med J 2015;62:A5082.
[12] Winter MC. Treatment of low-risk gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol 2021.
[13] Li J, Li S, Yu H, et al. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: a network meta-analysis. Gynecol Oncol 2018;148:247–53.
[14] Lewis Jr, Gore H, Hertig AT, et al. Treatment of trophoblastic disease. With rationale for the use of adjunctive chemotherapy at the time of indicated operation. Am J Obstet Gynecol 1966;96:710–22.
[15] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.